Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 20

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 20
---
 Exchange Act;                               |

| · | the requirement to file financial statements in accordance with accounting principles generally accepted 
 in the United States, or U.S. GAAP;                                                                      |

| · | the proxy rules, which impose certain disclosure and procedural requirements for proxy solicitations; 
 and                                                                                                   |

| · | the requirement to comply with Regulation FD, which imposes certain restrictions on the selective disclosure 
 of material information.                                                                                     |

In addition, our officers, directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our Ordinary Shares. Accordingly, an investor may receive less information about us than it would receive about a public company incorporated in the United States.

| 7 |

Additionally, we elect to
follow certain home country corporate governance practices instead of those otherwise required under the listing rules of NASDAQ.

Additional Information

For additional information
related to our business and operations, please refer to the reports incorporated herein by reference, including our Annual Report on Form
20-F for the year ended December 31, 2024, as filed with the SEC on April 11, 2025, and our Reports on Form 6-K, as filed with the SEC,
as described in the section titled “Incorporation of Certain Information by Reference.”

| 8 |

The Offering The following summary contains basic terms about this offering and the securities and is not intended to be complete. It may not contain all of the information that is important to you. You should read the more detailed information contained in this prospectus, including but not limited to, the risk factors beginning on page 14. For a more complete description of the terms of the securities, see the section of this prospectus entitled “Description of the Securities.”

| Securities offered by us |     | Up to 3,536,345 Units, each Unit consisting                                                                                              
 of one Depositary Share and one Series L Warrant to purchase one Depositary Share for cash or otherwise acquire such greater number      
 of Depositary Shares as determined in accordance with the provisions of the Series L Warrant upon a zero cash exercise price option.     
 This prospectus also relates to the offering of the Depositary                                                                           
 Shares issuable upon exercise of the Series L Warrants and Pre-Funded Warrants. To better understand the terms of the Series L Warrants, 
 you should carefully read the “Description of the Securities We Are Offering” section